Resveratrol for Fatty Liver: NAFLD/MASLD, Liver Fat & Enzyme Evidence

Resveratrol is not an established treatment for fatty liver disease. Human trials in nonalcoholic fatty liver disease (NAFLD)—the term used in most of the resveratrol literature—have produced conflicting results, and several well-controlled studies found no meaningful improvement in liver fat or core liver outcomes.

A 2020 meta-analysis of seven randomized trials involving 302 participants found no overall benefit across the analyzed NAFLD outcomes and reported an ALT increase signal. A newer 2026 umbrella review found moderate-certainty signals for selected outcomes, including hepatic steatosis in NAFLD, but umbrella results inherit the small, heterogeneous trials underneath them.

The strongest interpretation in 2026 is therefore not “resveratrol works” or “resveratrol never works.” It is that the liver evidence is inconsistent and not strong enough to recommend resveratrol as a stand-alone NAFLD/MASLD therapy.

NAFLD, MASLD and the resveratrol literature

Most resveratrol trials were published before the newer term metabolic dysfunction-associated steatotic liver disease (MASLD) became widely adopted. Those studies generally use the older term nonalcoholic fatty liver disease (NAFLD).

The populations overlap substantially, but the diagnostic frameworks are not identical. For accuracy, this page uses NAFLD when describing the original trials and uses NAFLD/MASLD when discussing the broader modern clinical question.

Resveratrol and fatty liver at a glance

Outcome	Human evidence	Interpretation
Liver fat	Mixed to null	Multiple RCTs failed to show superiority over placebo.
ALT / AST	Mixed	Some individual trials improve enzymes; meta-analytic evidence is inconsistent and one pooled analysis found an ALT increase signal.
Insulin resistance	Mixed	Positive results exist, but not consistently across NAFLD trials.
Inflammatory markers	Possible modest benefit	Some meta-analyses report lower TNF-α or hs-CRP even when liver outcomes remain null.
Fibrosis	Not established	No convincing evidence that resveratrol reverses clinically meaningful fibrosis.
Histologic improvement	Not established	Available controlled studies do not demonstrate reliable disease modification.
Weight loss in NAFLD	Small/inconsistent	Resveratrol is not a substitute for evidence-based weight management.

Why resveratrol looked promising for fatty liver

Fatty liver disease is tightly connected to insulin resistance, excess adiposity, lipid metabolism, oxidative stress and inflammation. Resveratrol influences several of these pathways in cells and animal models, including AMPK and mitochondrial signaling.

That gives the compound a strong mechanistic rationale. But fatty liver treatment requires more than mechanism. The clinically relevant question is whether oral supplementation reduces liver fat, improves liver injury, changes fibrosis or improves long-term liver outcomes in people.

Chachay 2014: 3 grams per day did not help

One of the most important negative trials randomized overweight or obese adults with NAFLD to 3 g/day of resveratrol or placebo for eight weeks.

Despite the very high dose, resveratrol did not improve the major NAFLD features or insulin-resistance outcomes. The investigators also observed liver-related changes interpreted as possible hepatic stress.

This trial is important for two reasons:

• A very high dose did not rescue efficacy.
• “Antioxidant” or “liver protective” should not be treated as an automatic safety assumption at multi-gram dosing.

Chen 2015: a positive randomized trial

A separate double-blind randomized trial enrolled 60 adults with NAFLD and used 300 mg twice daily for three months.

The study reported improvements in:

• ALT and AST
• fasting glucose
• LDL and total cholesterol
• HOMA-IR

This is legitimate positive human evidence. The limitation is that a three-month study with metabolic and ultrasound endpoints does not establish fibrosis reversal or long-term liver protection.

Heebøll 2016: no superiority over placebo after six months

A six-month randomized placebo-controlled study used 500 mg three times daily, or 1.5 g/day, in adults with transaminase elevation and suspected NAFLD.

Liver lipid content decreased within the resveratrol group, but the change was not superior to placebo. The trial did not establish improvement in the key disease outcomes.

It also contained a safety signal worth preserving in the evidence record: one participant developed febrile leukopenia and thrombocytopenia after resveratrol, with recurrence on re-exposure. A single case cannot define population risk, but it should not be erased from a high-dose safety discussion.

Kantartzis 2018: the largest notable liver-fat trial was null

A randomized double-blind placebo-controlled trial enrolled 112 overweight, obese and insulin-resistant adults and used 150 mg/day for 12 weeks.

Resveratrol did not reduce liver fat or improve the cardiometabolic risk markers. In fact, liver fat fell in the placebo group rather than the resveratrol group.

This trial is especially valuable because of its larger sample relative to many earlier NAFLD studies.

The 2020 meta-analysis: no overall NAFLD benefit

A 2020 systematic review and meta-analysis pooled seven randomized clinical trials with 302 participants. Doses ranged from 500 to 3,000 mg/day and treatment lasted approximately 56 to 180 days.

The pooled analysis found no significant improvement in the major analyzed outcomes, including anthropometrics, lipids, glucose metabolism, blood pressure and most liver markers. ALT showed an increase signal.

The authors concluded that available evidence was insufficient to confirm resveratrol efficacy for NAFLD.

So why does the 2026 umbrella review show a steatosis signal?

The 2026 umbrella review synthesized prior systematic reviews and meta-analyses rather than directly rerunning every individual patient trial. It found moderate-certainty evidence for several NAFLD-related associations, including lower glucose, lower diastolic blood pressure and an improvement in hepatic steatosis.

This does not invalidate the negative trials. It illustrates how evidence synthesis can depend on:

• which meta-analysis is selected
• how hepatic steatosis was measured
• the number and size of underlying studies
• dose and duration
• population differences
• statistical model and heterogeneity

When umbrella-level signals conflict with multiple direct null RCTs, the correct conclusion is uncertainty—not certainty in whichever direction is commercially convenient.

Does resveratrol lower ALT and AST?

Not consistently. The Chen trial reported lower transaminases, while other trials did not reproduce that benefit. The 2020 meta-analysis found no broad liver-enzyme improvement and detected an ALT increase signal.

Liver enzymes are also imperfect proxies for liver fat, inflammation and fibrosis. Normalization of ALT would not by itself establish disease reversal.

Does resveratrol reduce liver fat?

The direct evidence is inconsistent and several well-designed trials are null. High-dose resveratrol did not reliably reduce liver fat relative to placebo in Chachay or Heebøll, and the larger Kantartzis trial was also negative.

That weighs against a simple product claim such as “resveratrol removes fat from the liver.”

Can resveratrol reverse fatty liver?

No clinical evidence supports the word “reverse” as a general claim. Improvement in one metabolic biomarker or one imaging measure is not equivalent to resolving steatohepatitis or reversing fibrosis.

Current management of MASLD is built around the person’s metabolic risk profile: weight management when indicated, physical activity, management of diabetes and lipids, alcohol assessment, and evidence-based medical care.

Does resveratrol reduce liver inflammation?

This may be one of the more plausible signals. Some meta-analyses report reductions in inflammatory markers such as TNF-α and hs-CRP even when the main liver outcomes remain unchanged.

That is scientifically interesting but should be labeled correctly: a biomarker signal, not proof of disease modification.

Does resveratrol help fatty liver by causing weight loss?

Probably not to a clinically important degree. The latest high-level obesity evidence shows null-to-very-small average changes in body weight.

See Resveratrol for Weight Loss.

What dose has been tested in NAFLD?

The NAFLD literature includes a wide range, including approximately:

• 600 mg/day
• 1,500 mg/day
• 3,000 mg/day

The 2020 meta-analysis included trials ranging from 500 to 3,000 mg/day. This wide range has not produced a clear dose-response relationship.

High-dose null trials are another reason not to assume that more resveratrol equals more liver benefit.

See Resveratrol Dosage.

Is high-dose resveratrol safe for the liver?

High-dose studies do not justify a blanket “liver safe” claim. The Chachay trial raised a hepatic-stress concern, the 2020 pooled analysis found an ALT increase signal, and the Heebøll study included a serious hematologic reaction with recurrence on re-exposure in one participant.

These findings do not prove common toxicity, but they make self-directed multi-gram dosing particularly difficult to justify for an unproven indication.

Who should not self-treat fatty liver with resveratrol?

Anyone with known liver disease should avoid replacing medical evaluation with supplements. Fatty liver can coexist with fibrosis, viral hepatitis, alcohol-related liver disease, medication injury and other causes that require different management.

People taking multiple medications should also review Resveratrol Drug Interactions.

Bottom line

Resveratrol has a plausible metabolic and anti-inflammatory rationale for fatty liver, but the direct human efficacy evidence is too inconsistent to call it an effective NAFLD/MASLD treatment.

The strongest cluster should preserve both sides: the positive Chen trial and newer umbrella signals, but also the Chachay, Heebøll and Kantartzis null trials and the seven-RCT meta-analysis.

For metabolic context, read Resveratrol and Diabetes, Resveratrol for Weight Loss and Resveratrol Benefits. The full paper-level liver evidence is in the Resveratrol Data Center.